Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors

doi:10.3760/cma.j.cn371439-20220516-00114

Abstract

Abstract:

At present， tumor therapy has entered the era of immunotherapy. However， in recent years， it has been found that the application of immune checkpoint inhibitors after chest radiotherapy can not only play a synergistic anti-tumor effect， but also cause radiation recall pneumonitis （RRP）. RRP is a rare immune-related adverse reaction， which even leads to death in severe cases. It is of great significance to study the mechanisms and influencing factors of RRP caused by immune checkpoint inhibitors for strengthening the cognitive management of RRP and reducing the risk of RRP.

Key words: Immune checkpoint inhibitors, Immunotherapy, Radiotherapy, Pneumonia, Radiation pneumonitis

Zhang Jie, Wei Meizhuo, Zhao ling, Yi Shanyong. Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors[J]. Journal of International Oncology, 2022, 49(10): 577-580.

References 31

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108. doi: 10.1097/CM9.0000000000002108
[2]	Laird J, Leventhal J, Kanowitz J, et al. Radiation recall dermatitis after capecitabine in a patient with triple negative breast cancer[J]. Pract Radiat Oncol, 2021, 11(6): 448-452. DOI: 10.1016/j.prro.2021.06.001. doi: 10.1016/j.prro.2021.06.001
[3]	Ye X, Yang J, Stebbing J, et al. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report[J]. BMC Pulm Med, 2022, 22(1): 54. DOI: 10.1186/s12890-022-01846-x. doi: 10.1186/s12890-022-01846-x pmid: 35123465
[4]	McKay MJ, Foster R. Radiation recall reactions: an oncologic enigma[J]. Crit Rev Oncol Hematol, 2021, 168: 103527. DOI: 10.1016/j.critrevonc.2021.103527. doi: 10.1016/j.critrevonc.2021.103527
[5]	McGovern K, Ghaly M, Esposito M, et al. Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review[J]. Future Sci OA, 2019, 5(5): FSO378. DOI: 10.2144/fsoa-2018-0123. doi: 10.2144/fsoa-2018-0123
[6]	Cousin F, Desir C, Ben Mustapha S, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer[J]. Radiother Oncol, 2021, 157: 47-55. DOI: 10.1016/j.radonc.2021.01.001. doi: 10.1016/j.radonc.2021.01.001 pmid: 33453313
[7]	Wang YY, Tian XC, Zhu L, et al. Concomitant radiation recall der-matitis and radiation recall pneumonitis induced by pembrolizumab[J]. J Thorac Oncol, 2020, 15(10): e160-e162. DOI: 10.1016/j.jtho.2020.05.014. doi: 10.1016/j.jtho.2020.05.014
[8]	Chen Y, Huang Z, Xing L, et al. Radiation recall pneumonitis induced by anti-PD-1 blockade: a case report and review of the literature[J]. Front Oncol, 2020, 10: 561. DOI: 10.3389/fonc.2020.00561. doi: 10.3389/fonc.2020.00561 pmid: 32411597
[9]	Giuranno L, Ient J, De Ruysscher D, et al. Radiation-induced lung injury (RILI)[J]. Front Oncol, 2019, 9: 877. DOI: 10.1186/s12890-020-01376-4. doi: 10.3389/fonc.2019.00877 pmid: 31555602
[10]	Guo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging[J]. Exp Ther Med, 2019, 17(1): 244-250. DOI: 10.3892/etm.2018.6936. doi: 10.3892/etm.2018.6936 pmid: 30651789
[11]	Zhang Z, Zhou J, Verma V, et al. Crossed pathways for radiation-induced and immunotherapy-related lung injury[J]. Front Immunol, 2021, 12: 774807. DOI: 10.3389/fimmu.2021.774807. doi: 10.3389/fimmu.2021.774807
[12]	Jia XH, Geng LY, Jiang PP, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors[J]. J Exp Clin Cancer Res, 2020, 39(1): 284. DOI: 10.1186/s13046-020-01749-x. doi: 10.1186/s13046-020-01749-x
[13]	Lu L, Sun C, Su Q, et al. Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance[J]. Clin Exp Med, 2019, 19(4): 417-426. DOI: 10.1007/s10238-019-00571-w. doi: 10.1007/s10238-019-00571-w pmid: 31313081
[14]	Ullah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis[J]. Curr Opin Pulm Med, 2020, 26(4): 321-325. DOI: 10.1097/MCP.0000000000000682. doi: 10.1097/MCP.0000000000000682 pmid: 32427626
[15]	Roy S, Salerno KE, Citrin DE. Biology of radiation-induced lung injury[J]. Semin Radiat Oncol, 2021, 31(2): 155-161. DOI: 10.1016/j.semradonc.2020.11.006. doi: 10.1016/j.semradonc.2020.11.006 pmid: 33610273
[16]	Bukamur H, Katz H, Alsharedi M, et al. Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab[J]. South Med J, 2020, 113(11): 600-605. DOI: 10.14423/SMJ.0000000000001166. doi: 10.14423/SMJ.0000000000001166 pmid: 33140115
[17]	Chen X, Sheikh K, Nakajima E, et al. Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies[J]. Oncologist, 2021, 26(10): e1822-e1832. DOI: 10.1002/onco.13900. doi: 10.1002/onco.13900
[18]	Liu Y, Wang W, Shiue K, et al. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer[J]. Radiother Oncol, 2021, 156: 231-238. DOI: 10.1016/j.radonc.2020.10.015. doi: 10.1016/j.radonc.2020.10.015
[19]	Shintani T, Kishi N, Matsuo Y, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab[J]. Clin Lung Cancer, 2021, 22(5): 401-410. DOI: 10.1016/j.cllc.2021.01.017. doi: 10.1016/j.cllc.2021.01.017 pmid: 33678582
[20]	Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications[J]. BMC Med, 2020, 18(1): 275. DOI: 10.1186/s12916-020-01718-3. doi: 10.1186/s12916-020-01718-3 pmid: 32943072
[21]	Teng F, Meng X, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review[J]. Cancer Lett, 2018, 414: 166-173. DOI: 10.1016/j.canlet.2017.11.014. doi: S0304-3835(17)30732-2 pmid: 29155348
[22]	Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radia-tion-induced lung injury: current evidence[J]. BMC Pulm Med, 2021, 21(1): 9. DOI: 10.1186/s12890-020-01376-4. doi: 10.1186/s12890-020-01376-4 pmid: 33407290
[23]	Riemann D, Cwikowski M, Turzer S, et al. Blood immune cell biomarkers in lung cancer[J]. Clin Exp Immunol, 2019, 195(2): 179-189. DOI: 10.1111/cei.13219. doi: 10.1111/cei.13219 pmid: 30246868
[24]	符伶俐, 李萍, 张芮, 等. 胸部肿瘤患者辐射性肺炎的发生和预测因素[J]. 国际肿瘤学杂志, 2020, 47(2): 107-111. DOI: 10.3760/cma.j.issn.1673-422X.2020.02.009. doi: 10.3760/cma.j.issn.1673-422X.2020.02.009
[25]	王慧, 夏茸, 魏清雯, 等. 非小细胞肺癌免疫检查点抑制剂相关性肺炎的危险因素及预测生物标志物[J]. 国际肿瘤学杂志, 2021, 48(5): 296-301. DOI: 10.3760/cma.j.cn371439-20210115-00057. doi: 10.3760/cma.j.cn371439-20210115-00057
[26]	Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156. DOI: 10.1016/j.lungcan.2018.09.015. doi: S0169-5002(18)30574-9 pmid: 30429014
[27]	Gomatou G, Tzilas V, Kotteas E, et al. Immune checkpoint inhibitor-related pneumonitis[J]. Respiration, 2020, 99(11): 932-942. DOI: 10.1159/000509941. doi: 10.1159/000509941 pmid: 33260191
[28]	Riviere P, Sumner W, Cornell M, et al. Radiation recall pneumonitis after treatment with checkpoint blockade immunotherapy: a case series and review of literature[J]. Front Oncol, 2021, 11: 662954. DOI: 10.3389/fonc.2021.662954. doi: 10.3389/fonc.2021.662954
[29]	Nakamura K, Okubo K, Takahashi T, et al. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma[J]. IJU Case Rep, 2019, 2(1): 30-33. DOI: 10.1002/iju5.12032. doi: 10.1002/iju5.12032
[30]	Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab[J]. Cancer Med, 2020, 9(13): 4622-4631. DOI: 10.1002/cam4.3113. doi: 10.1002/cam4.3113
[31]	Saito G, Oya Y, Taniguchi Y, et al. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)[J]. Lung Cancer, 2021, 161: 86-93. DOI: 10.1016/j.lungcan.2021.08.019. doi: 10.1016/j.lungcan.2021.08.019 pmid: 34543942